150 related articles for article (PubMed ID: 37639063)
1. Ultrasound and clinicopathological characteristics-based model for prediction of pathologic response to neoadjuvant chemotherapy in HER2-positive breast cancer: a case-control study.
Sui L; Yan Y; Jiang T; Ou D; Chen C; Lai M; Ni C; Zhu X; Wang L; Yang C; Li W; Yao J; Xu D
Breast Cancer Res Treat; 2023 Nov; 202(1):45-55. PubMed ID: 37639063
[TBL] [Abstract][Full Text] [Related]
2. Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients.
Baumgartner A; Tausch C; Hosch S; Papassotiropoulos B; Varga Z; Rageth C; Baege A
Breast; 2018 Jun; 39():19-23. PubMed ID: 29518677
[TBL] [Abstract][Full Text] [Related]
3. Combined conventional ultrasonography with clinicopathological features to predict axillary status after neoadjuvant therapy for breast cancer: A case-control study.
Yan Y; Jiang T; Sui L; Ou D; Qu Y; Chen C; Lai M; Ni C; Liu Y; Wang Y; Xu D
Br J Radiol; 2023 Dec; 96(1152):20230370. PubMed ID: 37750854
[TBL] [Abstract][Full Text] [Related]
4. Early prediction of treatment response to neoadjuvant chemotherapy based on longitudinal ultrasound images of HER2-positive breast cancer patients by Siamese multi-task network: A multicentre, retrospective cohort study.
Liu Y; Wang Y; Wang Y; Xie Y; Cui Y; Feng S; Yao M; Qiu B; Shen W; Chen D; Du G; Chen X; Liu Z; Li Z; Yang X; Liang C; Wu L
EClinicalMedicine; 2022 Oct; 52():101562. PubMed ID: 35928032
[TBL] [Abstract][Full Text] [Related]
5. Individualized model for predicting pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: A multicenter study.
Qian B; Yang J; Zhou J; Hu L; Zhang S; Ren M; Qu X
Front Endocrinol (Lausanne); 2022; 13():955250. PubMed ID: 36060977
[TBL] [Abstract][Full Text] [Related]
6. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
7. Exploring the influencing factors of the pathologic complete response in estrogen receptor-positive, HER2-negative breast cancer after neoadjuvant chemotherapy: a retrospective study.
Tang L; Shu X; Tu G
World J Surg Oncol; 2022 Jan; 20(1):27. PubMed ID: 35093083
[TBL] [Abstract][Full Text] [Related]
8. Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer.
Xiao Y; Ding J; Ma D; Chen S; Li X; Yu K
Front Immunol; 2022; 13():877825. PubMed ID: 35663978
[TBL] [Abstract][Full Text] [Related]
9. Nomogram based on quantitative dynamic contrast-enhanced magnetic resonance imaging, apparent diffusion coefficient, and clinicopathological features for early prediction of pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy.
He M; Su J; Ruan H; Song Y; Ma M; Xue F
Quant Imaging Med Surg; 2023 Jul; 13(7):4089-4102. PubMed ID: 37456283
[TBL] [Abstract][Full Text] [Related]
10. Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study.
Tang L; Li Z; Jiang L; Shu X; Xu Y; Liu S
Front Oncol; 2022; 12():999716. PubMed ID: 36605428
[TBL] [Abstract][Full Text] [Related]
11. Androgen Receptor as a Predictive Marker for Pathologic Complete Response in Hormone Receptor-Positive and HER-2-Negative Breast Cancer with Neoadjuvant Chemotherapy.
Lee EG; Lee DE; Kim HH; Han JH; Lee S; Kang HS; Lee ES; Chae H; Sim SH; Lee KS; Kwon Y; Jung SY
Cancer Res Treat; 2023 Apr; 55(2):542-550. PubMed ID: 36097802
[TBL] [Abstract][Full Text] [Related]
12. Diffusion-weighted MRI for predicting pathologic response to neoadjuvant chemotherapy in breast cancer: evaluation with mono-, bi-, and stretched-exponential models.
Suo S; Yin Y; Geng X; Zhang D; Hua J; Cheng F; Chen J; Zhuang Z; Cao M; Xu J
J Transl Med; 2021 Jun; 19(1):236. PubMed ID: 34078388
[TBL] [Abstract][Full Text] [Related]
13. Accuracy of digital mammography, ultrasound and MRI in predicting the pathological complete response and residual tumor size of breast cancer after completion of neoadjuvant chemotherapy.
Sudhir R; Koppula VC; Rao TS; Sannapareddy K; Rajappa SJ; Murthy SS
Indian J Cancer; 2022; 59(3):345-353. PubMed ID: 33753611
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.
Jankowski C; Guiu S; Cortet M; Charon-Barra C; Desmoulins I; Lorgis V; Arnould L; Fumoleau P; Coudert B; Rouzier R; Coutant C; Reyal F
Breast Cancer Res Treat; 2017 Jan; 161(1):73-81. PubMed ID: 27807808
[TBL] [Abstract][Full Text] [Related]
15. Imaging and Clinicopathologic Features Associated With Pathologic Complete Response in HER2-positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Dual HER2 Blockade.
Yoon GY; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH; Kim JE; Kim SB
Clin Breast Cancer; 2020 Feb; 20(1):25-32. PubMed ID: 31519449
[TBL] [Abstract][Full Text] [Related]
16. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M
Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
[TBL] [Abstract][Full Text] [Related]
17. Laboratory indicators predict axillary nodal pathologic complete response after neoadjuvant therapy in breast cancer.
Chen P; Zhao T; Bi Z; Zhang ZP; Xie L; Liu YB; Song XG; Song XR; Wang CJ; Wang YS
Future Oncol; 2021 Jul; 17(19):2449-2460. PubMed ID: 33878939
[TBL] [Abstract][Full Text] [Related]
18. Pathologic Complete Response in HER2-Positive Breast Cancer Patients Receiving Trastuzumab in Neoadjuvant Setting.
Sheikh F; Nazir A; Yasmeen S; Badar F; Ahmad U; Siddiqui N
J Coll Physicians Surg Pak; 2019 Feb; 29(2):159-163. PubMed ID: 30700356
[TBL] [Abstract][Full Text] [Related]
19. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
[TBL] [Abstract][Full Text] [Related]
20. Predicting Axillary Response to Neoadjuvant Chemotherapy: Breast MRI and US in Patients with Node-Positive Breast Cancer.
Kim R; Chang JM; Lee HB; Lee SH; Kim SY; Kim ES; Cho N; Moon WK
Radiology; 2019 Oct; 293(1):49-57. PubMed ID: 31407967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
